Synthesis of Aspirin
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pain-Relievers
Pain-Relievers Pain. It is a common experience though the cause Ibuprofen/Naproxen and severity differ greatly. Lucky for us there are pain-relievers (analgesics). Purpose: To reduce inflammation, reduce pain (E.g. Headache, mild or moderate pain. More Which pain- effective than aspirin or reliever will be acetaminophen for relief the most menstrual cramps effective one (dysmenorrhea). for you? Adverse Reactions: Commonly used nausea, heartburn, pain relievers diarrhea, indigestion, are not only abdominal discomfort, used for mild bleeding and ulcers. pain but also fever reduction and inflammation. Choose your pain reliever wisely for the most Examples: Advil, Motrin, Nuprin, Metaprin. effective treatment possible. The following Aleve and naproxen are similar to ibuprofen, information will give you a brief outline for each but last longer. All must be taken with food. commonly used pain relieving substance. Not recommended for use by pregnant or There are generic forms of each of the pain breast-feeding women. relievers. The generic pain relievers are as effective as the “Name Brand” pain relievers, and Avoid if any history of aspirin sensitivity. cost considerably less. For more information ask your pharmacist or health practitioner. Acetaminophen Aspirin Purpose: reduce pain, reduce fever Purpose: To reduce inflammation, pain, fever, (E.g. headache, and low intensity pain (E.g. headache, joint fever) pain, muscle pain) Adverse Adverse Reactions: skin rash, hives, shortness Reactions: of breath, asthma, shock, edema (swelling), Stomach irritation, stomach irritation, bleeding and ulcers. skin rash much less common than with Examples: Bayer aspirin. Aspirin, Bayer Timed Release, generic Examples: Tylenol, Panadol, Aspirin Free, aspirin. Anacin and Apap. -
Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions. -
Attenuated Total Reflection Infrared Spectroscopy (ATR-IR) As an in Situ Technique for Dissolution Studies Abe S
Seton Hall University eRepository @ Seton Hall Seton Hall University Dissertations and Theses Seton Hall University Dissertations and Theses (ETDs) Summer 8-2011 Attenuated Total Reflection Infrared Spectroscopy (ATR-IR) as an In Situ Technique for Dissolution Studies Abe S. Kassis Seton Hall University Follow this and additional works at: https://scholarship.shu.edu/dissertations Part of the Biochemistry Commons Recommended Citation Kassis, Abe S., "Attenuated Total Reflection Infrared Spectroscopy (ATR-IR) as an In Situ Technique for Dissolution Studies" (2011). Seton Hall University Dissertations and Theses (ETDs). 1432. https://scholarship.shu.edu/dissertations/1432 Attenuated Total Reflection Infrared Spectroscopy (ATR-IR) as an In Situ Technique for Dissolution Studies by Abe S. Kassis Ph.D. DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Chemistry and Biochemistry of Seton Hall University Seton Hall University Department of Chemistry and Biochemistry 400 South Orange Avenue South Orange, New Jersey 07079 August 2011 DISSERTATION COMMITTEE APPROVALS We certify that we have read this thesis and that in our opinion it is sufficient in scientific scope and quality as a dissertation for the degree of Doctor of Philosophy APPROVED BY: Advisor, Seton Hall University Nicholas H. Snow, Ph.D. Member of Dissertation Committee, Seton Hall University Tarun ~el, Ph.D. Member of Dissertation Committee, Novartis Pharmaceuticals Corporation Q\A"b A lM~ en P. KeI;y, Ph.D. Chair, Department ofChemistry and Biochemistry, Seton Hall University [ii] "Although nature commences with reason and ends in experience it is necessary for us to do the opposite, that is to commence with experience and from this to proceed to investigate the reason." -Leonardo da Vinci [iii] Abstract Attenuated Total Reflection Infrared Spectroscopy (ATR-IR) as an in situ Technique for Dissolution Studies Dissolution studies are critical tests for measuring the performance, or rate of release, of a drug product. -
Salsalate Tablets, USP 500 Mg and 750 Mg Rx Only
SALSALATE RX- salsalate tablet, film coated ANDAPharm LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Salsalate Tablets, USP 500 mg and 750 mg Rx Only Cardiovascular Risk NSAIDs may cause an increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS). Salsalate tablets, USP is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS). DESCRIPTION Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration. Chemically, salsalate (salicylsalicylic acid or 2-hydroxybenzoic acid, 2-carboxyphenyl ester) is a dimer of salicylic acid; its structural formula is shown below. Chemical Structure: Inactive Ingredients: Colloidal Silicon Dioxide, D&C Yellow #10 Aluminum Lake, Hypromellose, Microcrystalline Cellulose, Sodium Starch Glycolate, Stearic Acid, Talc, Titanium Dioxide, Triacetin. CLINICAL PHARMACOLOGY Salsalate is insoluble in acid gastric fluids (<0.1 mg/mL at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. -
A History of Aspirin
Physicians, Fads, and Pharmaceuticals: A History of Aspirin Anne Adina Judith Andermann*, B.Sc., M.Phil. Cantab * To whom correspondence should be addressed: Faculty of Medicine, McGill University, 3655 Drummond St., Montreal, QC, Canada H3G 1Y6"Politics is not out there in society. Politics is down there in the laboratory." --Bruno Latour (1). Aspirin is a product of the late-nineteenth-century laboratory, pharmaceutical industry, and medical community. The prevailing scientific techniques, industrial approaches, and medical beliefs were instrumental in the development, promotion and reception of the drug. As a result, the present account does not extend further back than a few decades prior to the release of aspirin from the laboratories of Farbenfabriken vormals Friedrich Bayer & Co. in 1899. In contrast, much of the current literature on aspirin (2,3,4) attempts to trace the compound back to antiquity through the Ebers papyrus, the Hippocratic writings, and the works of Galen. Such histories tell a simple, linear tale of the numerous "discoveries" proposed to have led to the use of certain salicylate-containing plants, such as willow bark and wintergreen, or salicylate-related compounds, including salicilin and salicylic acid, as cures for a variety of ailments. Indeed, according to Mann and Plummer: Both [salicilin and salicylic acid] attacked fever and pain, and their partisans advocated the salicylates' use as antiseptics, mouthwashes, and water preservatives for ocean voyages; one important chemist further suggested (erroneously) that sodium salicylate, a chemical relative, would successfully treat scarlet fever, diphtheria, measles, syphilis, cholera, rabies and anthrax (5). However, it is difficult to establish what effect, if any, these examples of the "historical" uses of "proto-aspirin" had on the impetus for and modes of developing and using the actual drug called aspirin. -
Salicylate, Diflunisal and Their Metabolites Inhibit CBP/P300 and Exhibit Anticancer Activity
RESEARCH ARTICLE Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Kotaro Shirakawa1,2,3,4, Lan Wang5,6, Na Man5,6, Jasna Maksimoska7,8, Alexander W Sorum9, Hyung W Lim1,2, Intelly S Lee1,2, Tadahiro Shimazu1,2, John C Newman1,2, Sebastian Schro¨ der1,2, Melanie Ott1,2, Ronen Marmorstein7,8, Jordan Meier9, Stephen Nimer5,6, Eric Verdin1,2* 1Gladstone Institutes, University of California, San Francisco, United States; 2Department of Medicine, University of California, San Francisco, United States; 3Department of Hematology and Oncology, Kyoto University, Kyoto, Japan; 4Graduate School of Medicine, Kyoto University, Kyoto, Japan; 5University of Miami, Gables, United States; 6Sylvester Comprehensive Cancer Center, Miami, United States; 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 8Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States; 9Chemical Biology Laboratory, National Cancer Institute, Frederick, United States Abstract Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-kB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct *For correspondence: everdin@ competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity gladstone.ucsf.edu search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate Competing interests: The and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells. -
Aspirin a Curriculum Resource for Post-16 Chemistry and Science Courses
Aspirin A curriculum resource for post-16 chemistry and science courses 1 Aspirin (2nd edition) Compiled by David Lewis Edited by Colin Osborne and Maria Pack Designed by Imogen Bertin and Sara Roberts First published by the Royal Society of Chemistry in 1998 Second edition published by the Royal Society of Chemistry in 2003 Printed by the Royal Society of Chemistry Copyright © Royal Society of Chemistry 2003 Registered charity No. 207890 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the UK Copyright Designs and Patents Act, 1988, this publication may not be reproduced, stored, or transmitted, in any form or by any means, without the prior permission in writing of the publishers, or in the case of reprographic reproduction, only in accordance with the terms of the licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of licences issued by the appropriate Reproduction Rights Organisation outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the Royal Society of Chemistry at the London address printed on this page. Notice to all UK Educational Institutions. The material in this book may be reproduced by photocopying for distribution and use by students within the purchasing institution providing no more than 50% of the work is reproduced in this way for any one purpose. Tutors wishing to reproduce material beyond this limit or to reproduce the work by other means such as electronic should first seek the permission of the Society. -
30. Synthesis of an Analgesic: Aspirin
30. Synthesis of an Analgesic: Aspirin A. Background Aspirin (acetylsalicylic acid) belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs), which work by blocking the synthesis of prostaglandins in the body. Before exploring the chemistry of aspirin, one should understand the biological process of inflammation. Inflammation in the body occurs in response to the presence of harmful stimuli including: the presence of a foreign organism, nerve damage, and tissue irritation. Symptoms of inflammation include: redness, swelling, pain, and loss of mobility at the affected site. The experience of pain in the body begins with some stimulus that invokes an immune response. To combat the stimulus, the brain signals the body to begin a number of biological cascade reactions that include the synthesis of histamine, bradykinin, and prostaglandins, all of which contribute to the experience of inflammation and pain. During an inflammation response, prostaglandins are synthesized from the ω-6 fatty acid, arachidonic acid, which O comes from our diet and can be OH synthesized in the body from linoleic acid. An important enzyme arachidonic acid in the conversion of arachidonic acid to prostaglandins is Cyclooxygenase-1 (COX-1) cyclooxygenase-1 (COX-1) which abstracts a hydrogen atom from O arachidonic acid to produce a radical intermediate. This reactive OH intermediate then undergoes a number of subsequent steps, eventually leading to the Steps production of prostaglandins (PGE2 is shown). Most anti- inflammatory drugs work by O inhibiting the prostaglandin synthesis pathway in some O OH manner. In the case of Aspirin, the COX-1 enzyme is deactivated by Prostaglandin PGE2 transfer of the aspirin acetyl group to an important –OH moiety of the HO COX enzyme. -
Chemistry: Essay
CHEMISTRY: ESSAY The History of Aspirin "The active ingredient in Aspirin, acetylsalicylic acid, was synthesised for the first time in a chemically pure and thus stable form in 1897 by a young chemist working for Bayer, Dr. Felix Hoffmann.” – Bayer Aspirin, chemically known as acetylsalicylic acid, is a versatile drug that treats a number of pains, from reducing fever to relieving joint pains. Acetylsalicylic acid was first produced in 1853 by French chemist Charles Frederic Gerhardt. However, 1897 saw German chemist Felix Hoffmann study Gerhardt’s experiments and as a result, truly “rediscovered” acetylsalicylic acid. Bayer, a German chemical and pharmaceutical company soon dubbed this drug as we now know it – aspirin, or the wonder drug. Aspirin-like substances date back to the Ancient Romans, in which willow bark was used as a means of reducing fever. The leaves and bark of the willow tree contain a similar chemical to acetylsalicylic acid called salicin, a naturally occurring compound. In 1763, English chaplain Edward Stone discovered this active ingredient, announcing at the Royal Society its potent ability to treat aches, fatigue, inflammation and other fever-like symptoms. Following this, several scientists of 19th century Europe sought to extract modest yields of salicin from willow bark. By the 1830s, salicylic acid was first discovered by Swiss pharmacist Johann Pagenstecher and later by Italian chemist Raffaele Piria. Initially, both scientists had not realised that they had discovered the same, new pain-reducing substance. However, it was only until 1890 that Carl Duisberg, head of research at Bayer, expanded the company’s research program by employing several pharmaceutical research teams, one of which included young Felix Hoffmann. -
Betamethasone and Salicylic Acid
PATIENT & CAREGIVER EDUCATION Betamethasone and Salicylic Acid This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada Diprosalic; RATIO-Topisalic What is this drug used for? It is used to treat skin irritation. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Fungal, TB (tuberculosis), or viral infection of the skin. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Betamethasone and Salicylic Acid 1/6 What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you. Do not use longer than you have been told by the doctor. -
The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition
Georgetown University Law Center Scholarship @ GEORGETOWN LAW 1992 Book Review: The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition Joseph A. Page Georgetown University Law Center, [email protected] This paper can be downloaded free of charge from: https://scholarship.law.georgetown.edu/facpub/1146 47 Food & Drug L.J. 459-481 (1992) (reviewing Charles C. Mann & Mark Plummer, The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition (1991)) This open-access article is brought to you by the Georgetown Law Library. Posted with permission of the author. Follow this and additional works at: https://scholarship.law.georgetown.edu/facpub Part of the Food and Drug Law Commons, and the Marketing Law Commons Book Review jOSEPH A. PAGE* The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Com petition, by Charles C. Mann and Mark Plummer. Published by Alfred A. Knopf, Inc. (201 E. 50th St., New York, N.Y. 10022) (1991). 420 pages. $25.00. l. INTRODUCTION The recent identification of a possible link between the long-term use of aspirin and a reduced incidence of colon and rectal cancer1 has directed renewed attention to a familiar household medication whose origins reach back to antiquity.2 Competition from other painkillers had begun to cut deeply into the market once dominated by aspirin-based products3 when studies indicated the possibilities, first that the regular consumption of aspirin might pre vent second heart attacks,4 and later that it might lower the risk of heart attacks in healthy individuals.5 If these two discoveries, as well as the new finding about colon and rectal cancers, hold up under further scientific scrutiny and gain acceptance within the medical and regulatory communi ties, the growth potential for the sale of medicines made from acetylsali cylic acid (the chemical name for aspirin) would be virtually unlimited. -
Opinion on Salicylic Acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019
SCCS/1601/18 Final Opinion Corrigendum of 20-21 June 2019 Scientific Committee on Consumer Safety SCCS OPINION ON salicylic acid (CAS 69-72-7) Submission I The SCCS adopted the final Opinion by written procedure on 21 December 2018 Corrigendum of 20-21 June 2019 SCCS/1601/18 Final Opinion Opinion on salicylic acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019 ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final Opinion The SCCS members: Dr U. Bernauer Dr L. Bodin Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri (Rapporteur) Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven External experts: Dr A. Simonnard Dr A. Koutsodimou Prof. W. Uter The additional contribution of the following external expert is gratefully acknowledged: Dr. N. von Goetz All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 10 September until 14 November 2018). Comments received during this time were considered by the SCCS. For this Opinion, comments received resulted in the following main changes: sections 3.3.1.1.